Jiangxi Saiji Biotechnology Co., Ltd.

Jiangxi Saiji Biotechnology Co., Ltd. was established in 2017 and is located in Nanchang High-tech Zone. It is a wholly-owned subsidiary of Hangzhou Saiji Biotechnology布局 in the central region and carries important R&D and production tasks of the parent company. The company focuses on the clinical translation of flow cytometry immunoassay technology, mainly centering on a novel flow cytometry immune platform, and has grown into a leading brand in the flow cytometry field of China's in vitro diagnostics industry. In 2022, the company invested nearly 9 million yuan in R&D, with more than 80% of its R&D products being domestic first-of-their-kind products. Its user base has covered 30 provinces nationwide, and its coverage rate among domestic hospitals has reached 70%.

Products and Services
The company focuses on the R&D and production of flow cytometry detection reagents and holds core technologies such as lyophilized reagents and fully automated flow cytometers. The domestic first "one-tube lyophilized lymphocyte subset absolute count reagent" developed and produced by the company has officially obtained the Class III medical device registration certificate from the National Medical Products Administration (NMPA), achieving a dual breakthrough in the "standardization" and "automation" of flow cytometry detection reagents. With "one-tube" + "lyophilization" as its core form, this product combines absolute count microspheres with antibodies to precisely quantify lymphocyte subsets in human peripheral blood, providing an important basis for the diagnosis, efficacy evaluation, and prognostic monitoring of various clinical diseases. In addition, the company has also launched a peripheral blood detection product for Alzheimer's disease, which can simultaneously detect 4 to 5 combined indicators at one time, and has successfully brought multiple new products to market.

Honors and Qualifications
The company has been recognized as a National High-tech Enterprise and a Jiangxi Province Specialized, Refined, Distinctive, and Innovative SME, and in 2023 was selected for the "2023 Science and Technology* and Registered Enterprises, High-growth Science and Technology Enterprises" list published by the Jiangxi Provincial Department of Science and Technology, and was awarded the title of Gazelle Enterprise.

Corporate Culture
The company upholds the principles of "quality first, customer supreme," aims to meet market demand and the ever-changing needs of customers, increases and accelerates the intensity of new product R&D, and is committed to bringing users a more convenient and intelligent experience through continuous innovation and high-quality products. The company will take technological innovation as its core driving force, empower the upgrading of the healthcare industry with more high-quality innovative achievements, and contribute wisdom and strength to advancing the construction of Healthy China.

(This introduction was intelligently generated by DeepSeek AI and is for reference only.)